Letter to the editor:

OBESITY PHARMACOTHERAPY: CURRENT STATUS

Parveen Kumar*, Uma Bhandari

Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University)

* Corresponding author: Parveen Kumar; Jamia Hamdard (Hamdard University), New Delhi -110062, India; E-mail: pkrathee@gmail.com

http://dx.doi.org/10.17179/excli2014-732

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

Dear Editor,

Obesity is a medical condition in which excess body fat has accumulated to such an extent that it may have an adverse effect on health, leading to reduced life expectancy (Haslam and James, 2005). The lifestyle treatments directed at improving diet and physical activity are considered as first line treatment for obesity; however, if these fail, antiobesity medication is recommended. In the past years, numerous drugs have been approved for the treatment of obesity; however, currently, orlistat is the only food and drug administration (FDA) approved drug for long term management of obesity (Table 1).

Lipolytic rate in white adipose tissue (WAT) has been positively and negatively correlated with indexes of insulin resistance and WAT de novo lipogenesis gene expression. It is a reasonable hypothesis that the difficulty in mobilizing lipids in adipocytes could contribute to increased adiposity and obesity, and thereby reducing the insulin sensitivity (Caminhotto et al., 2014). On the contrary, Girousse et al. (2013) has reported a new mechanism for the regulation of insulin sensitivity, who demonstrated that partial inhibition of lipolysis is via reduced action of hormone sensitive lipase (HSL), either by genetic modification or by pharmacological inhibition, reshapes the fatty acid fluxes without increase of fat mass; improving glucose metabolism through cell-autonomous induction of fat cell de novo lipogenesis and leading to improved insulin sensitivity in mice. Orlistat is a well-known inhibitor of pancreatic lipase (PL) that is also reported to inhibit HSL; thus inhibiting the stimulated lipolysis (Clifford et al., 2000; Bustanji et al., 2010). It is reported that inhibition of HSL improves lipid profile while reduces plasma glucose (Claus et al., 2005). In this context, inhibition of lipolysis with orlistat provides a mechanism for the decrease plasma free fatty acids (FFA) and improvement in insulin sensitivity. Hence, the control of metabolic activity in WAT stands out as an important therapeutic intervention in the treatment of metabolic diseases (Caminhotto et al., 2014).

Enç et al. (2009) reported that orlistat accelerates gastric emptying and attenuates gastric inhibitory peptide (GIP) release in healthy subjects; that play an important role in the modulation of lipid metabolism, obesity and insulin resistance. GIP, an insulinotropic hormone, is secreted from enteroendocrine upper gut K-cells postprandially. GIP similar to the incretin effect of glucagon-like peptide-1 (GLP-1), stimulates glucose-dependent insulin secretion. By acting on GIP receptors on adipocytes, GIP exhibits insulin mimetic properties such as elevation in glucose uptake, fatty acid synthesis, lipoprotein lipase synthesis, and reduction in glu-
cagon-induced lipolysis; resulting in fat accumulation in adipocytes, obesity and insulin resistance.

Apart from decreasing insulin resistance, orlistat is reported to increase postprandial GLP-1 levels; thereby enhancing the insulin sensitivity and blunting the postprandial rise in blood glucose in type 2 diabetic patients. Hence, increased GLP-1 levels, which lead to decreased food intake, may also contribute to the weight loss that is associated with the use of orlistat (Damci et al., 2004). Elevated anorectic gut hormones, such as GLP-1 and peptide YY (PYY), play a crucial role in the reduction in food intake. The long-term inhibition of intestinal lipase by orlistat increases the pre-prandial levels of GLP-1 and PYY, independent of body mass changes. Therefore, long-term treatment with orlistat may exert hunger suppressing and insulin sensitizing incretin effect beyond the weight reduction (Olszanecka-Glinianowicz et al., 2013).

Blood glucose control becomes increasingly challenging in the obese patient with type 2 diabetes after the failure of metformin monotherapy (Scheen, 2003; Niswender, 2010). Moderate weight loss is recommended in these patients, with the conjunctive use of weight loss medications. Orlistat is reported to be as effective as metformin in reducing body weight and insulin resistance in obese patients (Sari et al., 2004). As per earlier reports, a moderate weight loss with orlistat treatment resulted in greater improvement in FFA levels and insulin sensitivity in type 2 diabetics (Derosa et al., 2012; Olszanecka-Glinianowicz et al., 2013) as well as obese subjects (Tiikkainen et al., 2004; Derosa et al., 2010).

With respect to the future prospects point of view, obesity is set to be the world’s major cause of morbidity and mortality in the 21st Century. The year 2013 was a landmark for the field of obesity, as in June 2013, the American Medical Association recognizes obesity as a disease (AMA, 2013). The worldwide obesity prevalence continues to increase with a growing demand for effective and safe antiobesity drugs. In the last few years, despite promising results on reduction of body weight, many antiobesity drugs were withdrawn from the market due to serious adverse effects (Kang and Park, 2012). Currently, orlistat is the only FDA approved drug for long term management of obesity. Therefore, there is need for development of more effective and safe antiobesity drugs. Additionally, a lifestyle modification such as diet and exercise need to be focused as a positive approach for treatments for obesity as it remains the cornerstone in the management of obesity.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism of action</th>
<th>Status</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dinitrophenol</td>
<td>Increases metabolic rate</td>
<td>• Introduced 1933</td>
<td>Neuropathy, cataract and metabolic collapse</td>
</tr>
<tr>
<td>Amphetamines: dexamphetamine, methamphetamine</td>
<td>Norepinephrine (NE), Dopamine (DA) and 5-hydroxy tryptamine (5-HT) releaser (appetite suppression)</td>
<td>• Introduced 1936</td>
<td>Dependency and abuse potential, cardiovascular adverse effects such as hypertension (HT), tachycardia, nervousness and psychosis</td>
</tr>
<tr>
<td>Phenylpropanolamine</td>
<td>NE, DA and 5-HT releaser (appetite suppression)</td>
<td>• Introduced 1939-US</td>
<td>Cardiac arrest, increase risk of hemorrhagic stroke (especially women), arrhythmias, myocardial infarction, pulmonary HT</td>
</tr>
<tr>
<td>Diethylpropion</td>
<td>NE releaser, and NE and DA reuptake inhibitor (appetite suppression)</td>
<td>• Introduced 1959</td>
<td>Psychosis, nervousness, insomnia, transient ischemic attack and pulmonary HT</td>
</tr>
<tr>
<td>Phentermine</td>
<td>NE and DA reuptake inhibitor (appetite suppression)</td>
<td>• Introduced 1959-US</td>
<td>Insomnia, tremor, increase blood pressure, headache and palpitation</td>
</tr>
<tr>
<td>Aminorex</td>
<td>5-HT releaser and reuptake inhibitor; potent monoamine oxidase inhibitor (appetite suppression)</td>
<td>• Introduced 1965-Europe</td>
<td>Pulmonary HT</td>
</tr>
<tr>
<td>Mazindol</td>
<td>NE reuptake inhibitor</td>
<td>• Introduced 1970</td>
<td>Nervousness, atrial fibrillation, insomnia, syncope and pulmonary HT</td>
</tr>
<tr>
<td>Fenfluramine</td>
<td>5HT releaser and reuptake inhibitor (appetite suppression)</td>
<td>• Introduced 1963-Europe, 1973-US</td>
<td>Valvular heart disease and pulmonary HT</td>
</tr>
<tr>
<td>Dexfenfluramine</td>
<td>5HT releaser and reuptake Inhibitor (appetite suppression)</td>
<td>• Introduced 1985-Europe, 1996-US</td>
<td>Valvular heart disease and pulmonary HT</td>
</tr>
<tr>
<td>Sibutramine</td>
<td>Selective serotonin and NE reuptake inhibitor (appetite suppression)</td>
<td>• Introduced 1997-US</td>
<td>Increased risk of heart attack and stroke in high-risk cardiac patients</td>
</tr>
<tr>
<td>Rimonabant</td>
<td>Selective cannabinoid-1 (CB-1) receptor blocker</td>
<td>• Introduced 2006-Europe</td>
<td>Potential of serious psychiatric disorders</td>
</tr>
<tr>
<td>Orlistat</td>
<td>Pancreatic lipase inhibitor (decreased fat absorption)</td>
<td>• Introduced 1999-USA</td>
<td>Abdominal pain, bloating, flatulence, oily stools, diarrhoea and decrease absorption of fat soluble vitamins</td>
</tr>
</tbody>
</table>
REFERENCES


